Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+0.42%
-0.09%
-2.69%
URGN
UroGen Pharma Ltd. O
$7.31
Chart
9.96
9.74
11.08
13.13
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+0.42%
-0.09%
-2.69%
URGN
UroGen Pharma Ltd. O
Current Price
$7.31
Login to view UroGen Pharma Ltd. O (URGN) recommendation from the last 90 days from financial news and social media.
Chart
9.96
9.74
11.08
13.13
URGN Latest Headlines
Securities Fraud Investigation Into UroGen Pharma Ltd. (URGN) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz. announces an investigation of UroGen Pharma Ltd. (UroGen or the Company) (NASDAQ: ) on behalf of investors concerning the Company'.s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON UROGEN PHARMA LTD. (URGN) CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.What Is The Investig
Today
INVESTOR ALERT: Investigation of UroGen Pharma Ltd. (URGN) Announced by Holzer & Holzer LLC. ) complied with federal securities laws. On May 16 2025 the FDA stated: Given that ENVISION lacked a concurrent control arm the primary endpoints of complete response (CR) and duration of response (DOR) are difficult to interpret. While CR indicates drug activity of UGN-102 it is unclear whether the observed DOR can be attributed to the investigational product or instead reflects ...
Today
UroGen Pharma misses top-line and bottom-line estimates. reaffirms FY25 outlook.
Mon May 12, 2025
A Look at UroGen Pharmas Upcoming Earnings Report. UroGen Pharma (NASDAQ:) is preparing to release its quarterly earnings on Monday 2025-05-12. Here'.s a brief overview of what investors should keep in mind before the announcement.Analysts expect UroGen Pharma to report an UroGen Pharma s will hope to hear the company announce they'.ve not only beaten that estimate but also to provide positive guidance or forecasted growth for the next ...
Fri May 9, 2025
UroGen Pharma Touts Four-Year Response With Urothelial Cancer Drug Study Highlights Potential For Bladder Cancer Candidates. ) on Sunday highlighted a duration of response of nearly four years from a long-term follow-up study with Jelmyto(mitomycin) .The United States Food And Drug Administration approved Jelmyto in 2020 for low-grade upper tract urothelial cancer (LG-UTUC) in adults.Among patients from the OLYMPUS trial who achieved a complete response after primary chemoablation with Jelmyto (
Mon Apr 28, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
URGN Stock trends
URGN Stock performance
URGN Stock analysis
URGN investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
